Read by QxMD icon Read

Gynecologic Oncology

Elizabeth V Connor, Erica M Newlin, J Eric Jelovsek, Mariam M AlHilli
OBJECTIVE: To externally validate a model predicting non-home discharge in women undergoing primary cytoreductive surgery (CRS) for epithelial ovarian cancer (EOC). METHODS: Women undergoing primary CRS via laparotomy for EOC at three tertiary medical centers in an academic health system from January 2010 to December 2015 were included. Patients were excluded if they received neoadjuvant chemotherapy, had a non-epithelial malignancy, were not undergoing primary cytoreduction, or lacked documented model components...
August 11, 2018: Gynecologic Oncology
S P Bisch, T Wells, L Gramlich, P Faris, X Wang, D T Tran, N X Thanh, S Glaze, P Chu, P Ghatage, J Nation, V Capstick, H Steed, J Sabourin, G Nelson
OBJECTIVE: Enhanced recovery pathways have been shown to reduce length of stay without increasing readmission or complications in numerous areas of surgery. Uptake of gynecologic oncology ERAS guidelines has been limited. We describe the effect of ERAS guideline implementation in gynecologic oncology on length of stay, patient outcomes, and economic impact for a province-wide single-payer system. METHODS: We compared pre- and post-guideline implementation outcomes in consecutive staging and debulking patients at two centers that provide the majority of surgical gynecologic oncology care in Alberta, Canada between March 2016 and April 2017...
August 9, 2018: Gynecologic Oncology
Boris J Winterhoff, Makayla Maile, Amit Kumar Mitra, Attila Sebe, Martina Bazzaro, Melissa A Geller, Juan E Abrahante, Molly Klein, Raffaele Hellweg, Sally A Mullany, Kenneth Beckman, Jerry Daniel, Timothy K Starr
No abstract text is available yet for this article.
August 7, 2018: Gynecologic Oncology
Kathleen N Moore, David M O'Malley, Ignace Vergote, Lainie P Martin, Antonio Gonzalez-Martin, Karim Malek, Michael J Birrer
PURPOSE: To evaluate the safety profile and preliminary antitumor activity of mirvetuximab soravtansine when administered in combination with carboplatin to relapsed ovarian cancer patients. METHODS: Patients with recurrent, platinum-sensitive epithelial ovarian or fallopian tube cancer were enrolled. Eligibility included a minimum requirement of tumor FRα positivity (≥25% of cells with ≥2+ staining intensity). Patients received escalating doses of mirvetuximab soravtansine and carboplatin on day 1 of a 21-day cycle (once every 3 weeks)...
August 6, 2018: Gynecologic Oncology
Ayumu Matsuoka, Shinichi Tate, Kyoko Nishikimi, Makio Shozu
No abstract text is available yet for this article.
August 4, 2018: Gynecologic Oncology
Luana L S Rodrigues, Mariza G Morgado, Vikrant V Sahasrabuddhe, Vanessa S De Paula, Nathália S Oliveira, Elena Chavez-Juan, Diane M Da Silva, W Martin Kast, Alcina F Nicol, José H Pilotto
OBJECTIVE: We evaluated acceptability of cervico-vaginal self-collection (CVSC) and prevalence of human papillomavirus (HPV) in Human immunodeficiency virus (HIV)-infected and HIV-uninfected women living in the Tapajós region, Amazon, Brazil. METHODS: Cross-sectional study recruited 153 non-indigenous women (HIV-uninfected, n = 112 and HIV-infected, n = 41) who voluntarily sought assistance in health services. Peripheral blood for HIV screening and cervical scraping (CS) for HPV detection were collected...
August 4, 2018: Gynecologic Oncology
Adrianne Mallen, T Rinda Soong, Mary K Townsend, Robert M Wenham, Christopher P Crum, Shelley S Tworoger
Given the current lack of effective screening for ovarian cancer, surgical removal of at-risk tissue is the most successful strategy to decrease risk of cancer development. However, the optimal timing of surgery and tissues to remove, as well as the appropriate patients to undergo preventive procedures are poorly understood. In this review, we first discuss the origin and precursors of ovarian epithelial carcinomas, focusing on high-grade serous carcinomas and endometriosis-associated carcinomas, which cause the majority of the mortality and incidence of ovarian cancer...
August 4, 2018: Gynecologic Oncology
Z D Horne, M J Dohopolski, D Pradhan, R Bhargava, R P Edwards, J L Kelley, J T Comerci, A B Olawaiye, M B Courtney-Brooks, M M Bockmeier, J L Berger, S E Taylor, P Sukumvanich, S Beriwal
PURPOSE: Human papillomavirus (HPV) is implicated as a causative factor in vulvar squamous cell carcinoma (VSCC). This study evaluates if p16-positivity, a surrogate for HPV, predicts for better response rates to chemoradiation therapy and survival. MATERIALS AND METHODS: We conducted a retrospective chart review of women treated with neoadjuvant or definitive chemoradiation (CRT) therapy from 2000 to 2016 for VSCC. p16 stain-positivity was defined as diffuse strong "block" immunoreactivity within invasive tumor...
August 3, 2018: Gynecologic Oncology
Ang Li, Rong Xie, Qihuan Zhi, Yixiao Deng, Yangming Wu, Weiwei Li, Lu Yang, Zinan Jiao, Jiaqi Luo, Yi Zi, Gang Sun, Jiajia Zhang, Yujian Shi, Jian Liu
OBJECTIVE: To investigate the BRCA status in Chinese patients with ovarian cancer (OC). Though there were two large prevalence studies in Chinese OC patients, this was the first time to observe it in healthy controls. METHODS: We performed BRCA mutation screening using next-generation sequencing to determine the prevalence of BRCA germline deleterious mutations in an unselected cohort of Chinese OC patients (n = 1331) versus healthy controls (n = 1763) and describe the types and spectrum of BRCA deleterious variants...
August 2, 2018: Gynecologic Oncology
B G Wortman, T Bosse, R A Nout, L C H W Lutgens, E M van der Steen-Banasik, H Westerveld, H van den Berg, A Slot, K A J De Winter, K W Verhoeven-Adema, V T H B M Smit, C L Creutzberg
OBJECTIVE: The Post-Operative Radiation Therapy in Endometrial Carcinoma (PORTEC)-4a trial is a randomized trial for women with high-intermediate risk endometrial cancer (EC), comparing individualized adjuvant treatment based on a molecular-integrated risk profile to standard adjuvant treatment; vaginal brachytherapy. To evaluate patient acceptability and pathology logistics of determining the risk profile, a pilot phase was included in the study. METHODS: PORTEC-4a is ongoing and the first 50 patients enrolled were included in the pilot phase...
August 2, 2018: Gynecologic Oncology
Mauricio P Pinto, Carlos Balmaceda, Maria L Bravo, Sumie Kato, Alejandra Villarroel, Gareth I Owen, Juan Carlos Roa, Mauricio A Cuello, Carolina Ibañez
BACKGROUND: High-grade serous ovarian cancer (HGSOC) is the most prevalent and aggressive histologic type of ovarian cancer. To date, there are no reliable biomarkers to effectively predict patient prognosis. Studies have demonstrated inflammation and tumor infiltrating lymphocytes (TILs) correlate with a bad and good prognosis, respectively. Here, we sought to evaluate systemic inflammation and TILs as early prognostic markers of survival. METHODS: Neutrophil-to-lymphocyte ratio (NLR) and serum Lactate Dehydrogenase (LDH) were used as indicators of systemic inflammation...
August 2, 2018: Gynecologic Oncology
Justin Wilford, Kathryn Osann, Susie Hsieh, Bradley Monk, Edward Nelson, Lari Wenzel
OBJECTIVES: Cervical cancer patients are at high risk for emotional distress. In this study we evaluate the PROMIS emotional distress-Depression and -Anxiety Short Forms for assessing depression and anxiety in a cervical cancer population. METHODS: A 15-item questionnaire was used in a cervical cancer biobehavioral randomized clinical trial, testing psychosocial telephone counseling (PTC) against usual care (UC). It was administered to 204 patients prior to randomization, four months post-enrollment, and nine months post-enrollment, together with legacy measures of depression...
August 2, 2018: Gynecologic Oncology
Jessica Lee, Lindsay R Gubernick, Allison L Brodsky, Julia E Fehniger, Douglas A Levine, Deanna Gerber, Shabnam A Asgari, Anna Cantor, Jessica T Martineau, Ophira M Ginsburg, Julia A Smith, Bhavana Pothuri
OBJECTIVES: Lynch syndrome (LS) accounts for the majority of inherited endometrial cancers (EC), and the identification of probands presents a unique opportunity to treat and prevent multiple cancers. The diagnosis of EC can provide the indication for women with specific risk factors to undergo genetic testing (GT). We sought to evaluate genetic counseling referrals (GCR) and subsequent GT rates in an ethnically diverse group of high-risk women. METHODS: All women diagnosed with EC between 2011 and 2016 were identified...
August 1, 2018: Gynecologic Oncology
Kian Behbakht, David E Cohn, J Michael Straughn
No abstract text is available yet for this article.
July 30, 2018: Gynecologic Oncology
Mihae Song, Muthu N Kumaran, Murugesan Gounder, Darlene G Gibbon, Wilberto Nieves-Neira, Ami Vaidya, Mira Hellmann, Michael P Kane, Brian Buckley, Weichung Shih, Paula B Caffrey, Gerald D Frenkel, Lorna Rodriguez-Rodriguez
PURPOSE: Preclinical studies performed in our laboratory have shown that high-dose selenium inhibits the development of carboplatin drug resistance in an ovarian cancer mouse xenograft model. Based on these data, as well as the potential serious toxicities of supranutritional doses of selenium, a phase I trial of a combination of selenium/carboplatin/paclitaxel was designed to determine the maximum tolerated dose, safety, and effects of selenium on carboplatin pharmacokinetics in the treatment of chemo-naive women with gynecologic cancers...
July 29, 2018: Gynecologic Oncology
Ignace Vergote, Roger von Moos, Luis Manso, Els Van Nieuwenhuysen, Nicole Concin, Cristiana Sessa
BACKGROUND: Tumor Treating Fields (TTFields) are an anti-mitotic therapy comprising continuous delivery of low-intensity alternating electric fields at intermediate frequencies to the tumor region by a home-use medical device. METHODS: The INNOVATE (EF-22) Study was a phase 2, single arm clinical trial, which tested the safety and efficacy of TTFields (200 kHz) in combination with weekly paclitaxel (weekly for 8 weeks and then on days 1, 8, 15 of each subsequent 28 day-cycle; starting dose 80 mg/m2 ) in 31 patients with recurrent, platinum-resistant ovarian carcinoma...
July 27, 2018: Gynecologic Oncology
Koji Matsuo, Erin A Blake, Hiroko Machida, Rachel S Mandelbaum, Lynda D Roman, Jason D Wright
OBJECTIVE: To examine incidences and risk factors for metachronous vulvar, vaginal, and anal malignancies after a cervical cancer diagnosis. METHODS: This is a retrospective study examining data from the Surveillance, Epidemiology, and End Result Program between 1973 and 2013. Cumulative incidences of vulvar, vaginal, and anal cancers after the diagnosis of cervical cancer were assessed (n = 79,050). Multivariable analysis was performed to determine independent risk factors for these metachronous cancers...
July 24, 2018: Gynecologic Oncology
Nicola S Meagher, Klaus Schuster, Andreas Voss, Timothy Budden, Chi Nam Ignatius Pang, Anna deFazio, Susan J Ramus, Michael L Friedlander
OBJECTIVE: Advanced stage mucinous ovarian cancers are diagnostically and therapeutically challenging. Histotype specific trials have failed due to low recruitment after excluding non-ovarian primaries. Mucinous ovarian cancers are commonly metastatic from other sites however lack definitive diagnostic markers. We suggest a classification of mucinous ovarian cancers of uncertain primary origin 'MO-CUPs' in clinical trials. This study aims to identify drug targets to guide treatment and future trials...
July 24, 2018: Gynecologic Oncology
Emily M Webster, William M Burke, Hannah M Ware, Bayley A Jones, Reena Vattakalam, Ana I Tergas, Jason D Wright, June Y Hou
OBJECTIVE: Patient reported outcomes (PRO) relating to treatment toxicities have been demonstrated to reliably evaluate adverse events in clinical trials. We assessed the user satisfaction of implementing a focused PRO questionnaire for patients with gynecologic cancers undergoing chemotherapy. METHODS: Patients with gynecologic cancers undergoing chemotherapy were prospectively identified after IRB approval from April 2017 to August 2017. We administered a 24-symptom questionnaire, adapted from the validated PRO version of the Common Terminology Criteria for Adverse Event, to enrolled participants at the beginning of two outpatient visits...
July 20, 2018: Gynecologic Oncology
Shin Nishio, Mototsugu Shimokawa, Kazuto Tasaki, Hiroki Nasu, Teruyuki Yoshimitsu, Ken Matsukuma, Atsumu Terada, Naotake Tsuda, Kouichiro Kawano, Kimio Ushijima
OBJECTIVE: Chemotherapy for advanced or recurrent endometrial cancer requires further development. Irinotecan hydrochloride (CPT-11) suppresses tumor growth in several endometrial cancer strains. The present study evaluated the anti-tumor activity and toxicity of CPT-11 in patients with advanced or recurrent endometrial cancer. METHODS: Enrolled patients had advanced endometrial cancer with measurable lesions and received 2 pretreatment regimens. A 90-minute intravenous infusion of CPT-11 (100 mg/m2 ) was given on days 1, 8, and 15 of a 4-week cycle, aiming for an effect with ≤2 cycles...
July 20, 2018: Gynecologic Oncology
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"